Valeant Pharma adds $10 per share, contingent value right to cash-stock offer for Allergan
Valeant Pharmaceuticals is adding more cash to its offer to buy Botox maker Allergan in a bid that could now be worth more than $49 billion.
The Canadian drugmaker says it will now offer $58.30 and a portion of its stock for each Allergan share. It also promises a contingent value right shareholder payment based on future sales of a potential eye treatment.
The cash portion of that offer is up $10 from its previous bid of $48.30 per share, which Allergan Inc. rejected. That was part of an offer worth nearly $46 billion.
The new bid is worth about $49.5 billion, based on Tuesday’s closing price of $129.95 for Valeant Pharmaceuticals International Inc. shares and not counting the potential contingent value right payment.
News from © The Associated Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.
Join the Conversation!
Want to share your thoughts, add context, or connect with others in your community?
You must be logged in to post a comment.
